Skip to contentpdufa.bio

LIFYORLI (relacorilant): FDA NDA 220641

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 220641 is the FDA application for LIFYORLI (relacorilant). The FDA's Orange Book lists the applicant of record as CORCEPT THERAPEUTICS INC and the first approval on it as Mar 25, 2026. Code name used in development: CORT125134. Owner today: Corcept Therapeutics Incorporated (Nasdaq: CORT).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220641 · Orange Book NDA 220641

Names for this drug

Brand name (FDA)LIFYORLI
Orange Book trade name: LIFYORLI
Active ingredient (FDA)RELACORILANT
Code nameCORT125134
Source: Corcept Therapeutics press release, Nov 2, 2017
“relacorilant (the newly-approved generic name for CORT125134)”

Who holds the application

FDA applicant of recordCORCEPT THERAPEUTICS INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayCorcept Therapeutics Incorporated (CORT)
Source: Corcept Therapeutics press release, Mar 25, 2026
“Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery”

Products on NDA 220641 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001LIFYORLI (COPACKAGED)CAPSULE;ORAL100MG;25MGMar 25, 2026

FDA decisions we track for this drug

Relacorilant + nab-paclitaxel - (ROSELLA)CORT · DecidedRelacorilant - (GRACE resubmission)CORT · Upcoming

Drug page: /drug/relacorilant

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.